Status:
RECRUITING
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
Lead Sponsor:
Helen M. Bronte-Stewart
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Parkinson's Disease
Mild Cognitive Impairment
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognit...
Eligibility Criteria
Inclusion
- Diagnosis of Parkinson's disease (PD)
- Approved (or planning on) for subthalamic nucleus (STN) deep brain stimulation (DBS)
- Willingness to withdraw from clinical medication regimen when necessary for research visits
- Ability to provide informed consent
Exclusion
- Dementia
- Unstable medical, psychiatric conditions including significant untreated depression, history of suicidal attempt, or current suicide ideation
- History of seizures
- Pregnant
- Requires MRI
- Unable to walk 100 feet without an assistive device
Key Trial Info
Start Date :
April 8 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05968703
Start Date
April 8 2025
End Date
July 31 2027
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Neuroscience Health Center
Stanford, California, United States, 94305